Aurinia Closing In On Lupus Nephritis With Voclosporin
Phase III AURORA Study Reports Positive Top-Line Data
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
